Replies to post #154957 on Biotech Values

[DewDiligence]

EYEGV IPOs 7.86K* shares @$6.00:

http://finance.yahoo.com/news/eyegate-pharmaceuticals-inc-prices-4-232951345.html

EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EGP-437, the company's first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through EyeGate's proprietary innovative drug delivery system…

This is one of the smallest recent biotech IPOs.

*Assuming exercise of underwriter’s option.